Nephro Care India Ltd

Nephro Care India maintains a strong liquidity position with a current ratio of 2.01, indicating the company can cover its short-term obligations with its current assets. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. Free cash flow is negative at -237.0 million INR, primarily due to capital expenditures of -298.0 million INR, which may reflect ongoing investments in infrastructure or equipment. Profitability metrics show a return on equity (ROE) of 6.8% and a return on assets (ROA) of 5.33%. These figures are below the industry median for Healthcare Facilities & Services, which typically sees ROE and ROA in the 8-10% and 6-7% ranges, respectively. The company's operating margin is 7.6%, calculated as operating income of 34.9 million INR on revenue of 460.3 million INR, which is in line with the industry average. The company's revenue is concentrated in a single business segment focused on kidney-related healthcare services. There is no disclosed geographic diversification beyond India, where the company operates multiple clinics. This concentration may expose the company to regional economic or regulatory risks. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the next fiscal year. The company's capital expenditures suggest a focus on maintaining and expanding its service offerings, which may support long-term growth but could pressure short-term cash flow. Risk factors include the company's reliance on a single business model and geographic market. The absence of long-term debt and low dilution risk is a positive, but the negative free cash flow and high capital expenditures may limit flexibility. No immediate filing-based liquidity or dilution flags were detected, and the company has not issued shares recently. Recent filings and transcripts do not indicate any major strategic shifts or operational disruptions. The company continues to focus on its core renal care services and has not disclosed any new product lines or market expansions. The absence of recent events suggests a stable but potentially slow-growth environment.